Publication: Asian outpatients with schizophrenia: A double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol
Issued Date
2006-09-15
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-33748518379
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.89, No.8 (2006), 1157-1170
Suggested Citation
Ronnachai Kongsakon, Pureza Trinidad-Oate, Haroon Rashid Chaudhry, Syed Baqar Raza, Cynthia R. Leynes, Inam Ur Rehman Khan, Hasanah Che Ismail, Benjamin Chan, Joy C. Ignacio, Sonia C. Rodriguez, Amanda J. Lowry, Alan J.M. Brnabic, Robert Buenaventura Asian outpatients with schizophrenia: A double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. Journal of the Medical Association of Thailand. Vol.89, No.8 (2006), 1157-1170. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/23614
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Asian outpatients with schizophrenia: A double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol
Other Contributor(s)
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Cebu Doctors Hospital
Fatima Jinnah Medical College
General Hospital
St. Luke's Medical Center Quezon City
KV S.I.T.E. Hospital
School of Medical Sciences - Universiti Sains Malaysia
Hospital Permai
Jose R. Reyes Memorial Medical Center
Eli Lilly Australia Pty Ltd.
Eli Lilly (Philippines), Inc.
Mahidol University
Cebu Doctors Hospital
Fatima Jinnah Medical College
General Hospital
St. Luke's Medical Center Quezon City
KV S.I.T.E. Hospital
School of Medical Sciences - Universiti Sains Malaysia
Hospital Permai
Jose R. Reyes Memorial Medical Center
Eli Lilly Australia Pty Ltd.
Eli Lilly (Philippines), Inc.
Mahidol University
Abstract
To examine the quality of life (QoL) and clinical outcomes for Asian schizophrenic outpatients treated with olanzapine or haloperidol. Patients were randomized to 24-weeks' treatment with either olanzapine (n = 144) or haloperidol (n = 132) in a double-blind, prospective, multi-country study. The QLS and WHO-BREF were assessed for QoL; the PANSS, BPRS and CGI scales for clinical status; the BAS, AIMS and SAS scales for physical dysfunction. Regardless of antipsychotic, QoL improved significantly at 8 weeks and maintained this improvement at 24 weeks. Compared with haloperidol, olanzapine treatment was associated with significantly better QoL in the WHO-BREF physical and social relationship domains, better improvements in extrapyramidal symptoms in BAS and SAS scores, as well as lower incidence of adverse events. Patients taking haloperidol were more likely to be co-prescribed anticholinergics. The comparatively superior side-effect profile and tolerability of olanzapine may have contributed to enhance domain-specific QoL for these Asian outpatients.